Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer

Completed · Phase 2 · Has a placebo group

Conditions studied: Prostate Cancer

In brief

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. The use of eflornithine (DMFO) may be an effective way to prevent the development of prostate cancer. PURPOSE: Randomized phase II trial to determine the effectiveness of eflornithine in preventing prostate cancer in patients who are at high risk of developing the disease.

Key facts

Study ID

NCT00006101

Run by

Thomas E. Ahlering

People needed

76

Starts

1998-10-01

Expected to finish

2012-12-01

Last updated by the study team

2018-05-14

Who can join

Age: 35 and older, up to 70. Sex: male. Healthy volunteers: not accepted.

Where it is running

• Chao Family Comprehensive Cancer Center at University of California Irvine Cancer Center — Orange, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.